Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Blood (2020) 136 (2): 210–223.

https://doi.org/10.1182/blood.2019001417

Published: 2020

Includes: Supplemental data

Journal Articles

Integrin alpha6-Deletion Induces Apoptosis and Src Signaling Changes in Acute Lymphoblastic Leukemia Cells

Eun Ji Gang, MD PhD, Hye Na Kim, Johanna Scott, PhD, Matthew J Oberley, MDPhD, Etan Orgel, MD MS, Steven D. Mittelman, MDPhD, Yao-Te Hsieh, PhD, Markus Muschen, MD, Deepa Bhojwani, MD, Daniel Braas, PhD, Thomas Graeber, PhD, Nora Heisterkamp, PhD, Yong-Mi Kim, MD MPH, PhD

Blood (2017) 130 (Supplement 1): 3878.

https://doi.org/10.1182/blood.V130.Suppl_1.3878.3878

Published: 2017

Journal Articles

Enhanced Targeting of FLT3-ITD+AML Stem Cells through Combined Inhibition of SIRT1 and Autophagic Flux

Su Chu, MD, Yao-Te Hsieh, PhD, Marcus JGW Ladds, Sonia Lane, PhD, Ravi Bhatia, MD

Blood (2016) 128 (22): 31.

https://doi.org/10.1182/blood.V128.22.31.31

Published: 2016

Journal Articles

Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10

EunJi Gang, MDPhD, Yao-Te Hsieh, PhD, Hye Na Kim, Yann Duchartre, PhD, Shishido Stephanie, PhD, Markus Muschen, MD, Elizabeth Wayner, PhD, Nora Heisterkamp, PhD, Halvard Bonig, MD MA, Yong-Mi Kim, MDPhDMPH

Blood (2015) 126 (23): 2525.

https://doi.org/10.1182/blood.V126.23.2525.2525

Published: 2015

Journal Articles

Increased p53 Acetylation By SIRT1 Inhibition Is Required for Optimal Activation of p53 Activity and Significantly Enhances the Ability of HDM2 Inhibitors to Target CML LSC

Yann Pierre Kevin Duchartre, PhD, Ling Li, PhD, Tinisha McDonald, B.S., YinWei Ho, Yao-Te Hsieh, Ravi Bhatia, MD

Blood (2014) 124 (21): 4521.

https://doi.org/10.1182/blood.V124.21.4521.4521

Published: 2014

Journal Articles

PI3Kdelta Inhibitor, CAL-101, De-Adheres Primary Pre-B ALL from VCAM-1 and Induces Apoptosis in Primary Pre-B ALL

Sajad Khazal, MD, Enzi Jiang, MD PhD, Stephanie Shishido, Osanna Kosoyan, Kim Hye-Na, Alexa Velasquez, Yao-Te Hsieh, Hisham Abdel-Azim, MD, Ann M Mohrbacher, MD, Akil Merchant, MD, Alan S. Wayne, MD, Nora Heisterkamp, PhD, Yong-Mi Kim, MD MPH, PhD

Blood (2014) 124 (21): 3715.

https://doi.org/10.1182/blood.V124.21.3715.3715

Published: 2014

Journal Articles

VLA4 Blockade In Acute Myeloid Leukemia

Yao-Te Hsieh, Enzi Jiang, MD, PhD, Jennifer Pham, Hye-Na Kim, Hisham Abdel-Azim, MD, Sajad Khazal, MD, Gesine Bug, MD, PhD, Gabriele Spohn, Ph.D., Halvard Bonig, MD, MA, Yong-Mi Kim, MD, MPH, PhD

Blood (2013) 122 (21): 3944.

https://doi.org/10.1182/blood.V122.21.3944.3944

Published: 2013

Journal Articles

Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy

Blood (2013) 121 (10): 1814–1818.

https://doi.org/10.1182/blood-2012-01-406272

Published: 2013

Includes: Supplemental data

Journal Articles

The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Yao-Te Hsieh, Eun Ji Gang, MD, PhD, Halvard Bonig, MD, MA, Ronald J Biediger, PhD, Peter Vanderslice, PhD, Yong-Mi Kim, MD, MPH, PhD

Blood (2012) 120 (21): 1500.

https://doi.org/10.1182/blood.V120.21.1500.1500

Published: 2012

Journal Articles

Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.

Eun Ji Gang, MD, PhD, Yao-Te Hsieh, Huimin Geng, PhD, Jennifer Pham, Markus Muschen, MD, Adele de Arcangelis, Cheryl L Willman, MD, William L. Carroll, MD, Elisabeth Georges-Labouesse, Halvard Bonig, MD, MA, Yong-Mi Kim, MD, MPH, PhD

Blood (2012) 120 (21): 2565.

https://doi.org/10.1182/blood.V120.21.2565.2565

Published: 2012

Journal Articles

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia

Eugene Park, Eun Ji Gang, Yao-Te Hsieh, Paul Schaefer, Sanna Chae, Lars Klemm, Sandra Huantes, Mignon Loh, Edward M. Conway, Eun-Suk Kang, Hong Hoe Koo, Wolf-Karsten Hofmann, Nora Heisterkamp, Louis Pelus, Ganesan Keerthivasan, John Crispino, Michael Kahn, Markus Müschen, Yong-Mi Kim

Blood (2011) 118 (8): 2191–2199.

https://doi.org/10.1182/blood-2011-04-351239

Published: 2011

Includes: Supplemental data

Journal Articles

Adjuvant CD49d Blockade Eradicates Chemoresistant ALL

Yao-Te Hsieh, Eugene Park, Enzi Jiang, MD, PhD, Katrin Dauber, Doreen Chudziak, Paul Schaefer, Lars Klemm, Carlton Scharman, Eun-Suk Kang, MD, PhD, Hong-Hoe Koo, MD, PhD, Mignon L. Loh, M.D., Wolf Karsten Hofmann, MD, PhD, Nora Heisterkamp, Markus Muschen, MD, Hiroyuki Shimada, MD, Halvard Bonig, MD, MA, Yong-Mi Kim, MD, MPH

Blood (2010) 116 (21): 869.

https://doi.org/10.1182/blood.V116.21.869.869

Published: 2010

Journal Articles

Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia

Eugene Park, Enzi Jiang, MD, PhD, Yao-Te Hsieh, Lars Klemm, Cihangir Duy, Edward M. Conway, MD, PhD, FRCPC, MBA, Louis M. Pelus, PhD, John Crispino, PhD, Mignon L. Loh, M.D., Eun-Suk Kang, MD, PhD, Hong-Hoe Koo, MD, PhD, Allen Yang, MD, PhD, Nora Heisterkamp, PhD, Michael Kahn, PhD, Markus Muschen, MD, Yong-Mi Kim, MD, MPH

Blood (2010) 116 (21): 3263.

https://doi.org/10.1182/blood.V116.21.3263.3263

Published: 2010

Journal Articles

Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin

Enzi Jiang, MD, PhD, Eugene Park, Cu Nguyen, James Yoon, Yao-Te Hsieh, Mignon L. Loh, M.D., Markus Muschen, MD, Michael Kahn, Yong-mi Kim, MD, MPH

Blood (2010) 116 (21): 3264.

https://doi.org/10.1182/blood.V116.21.3264.3264

Published: 2010

Journal Articles

Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia.

Enzi Jiang, MD, PhD, Eugene Park, Carlton Scharman, Yao-Te Hsieh, Asha Kadavallore, Cu Nguyen, Yi Zhao, MD, Michael McMillan, PhD, John Groffen, PhD, Nora Heisterkamp, PhD, Markus Muschen, MD, Michael Kahn, PhD, Yong-Mi Kim, MD

Blood (2009) 114 (22): 3072.

https://doi.org/10.1182/blood.V114.22.3072.3072

Published: 2009

Journal Articles

Role of Survivin in Drug Resistant B-Cell Acute Lymphoblastic Leukemia.

Eugene Park, Enzi Jiang, MD, PhD, Gregor von Levetzow, Cihangir Duy, Lars Klemm, Yao-Te Hsieh, Asha Kadavallore, Hong Ma, PhD, Yi Zhao, MD, Cu Nguyen, John Groffen, PhD, Nora Heisterkamp, PhD, Markus Muschen, MD, Michael Kahn, PhD, Yong-Mi Kim, MD

Blood (2009) 114 (22): 10.

https://doi.org/10.1182/blood.V114.22.10.10

Published: 2009

Journal Articles

Preclinical Evaluation of Tysabri as a Novel Adjuvant Therapy against Drug Resistant B-ALL.

Yao-Te Hsieh, Enzi Jiang, MD, PhD, Carlton Scharman, Ella Waters, Eugene Park, Asha Kadavallore, Halvard Bonig, MA/MD, Yong-Mi Kim, MD, MPH, PhD

Blood (2009) 114 (22): 3089.

https://doi.org/10.1182/blood.V114.22.3089.3089

Published: 2009

Journal Articles

Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL

Enzi Jiang, MD, PhD, Min Yu, MD, PhD, Yao-Te Hsieh, Brian DeLaTorre, Asha Kadavallore, Carlton Scharman, Eugene Park, Allen S. Yang, MD, PhD, Markus Muschen, MD, John Groffen, PhD, Nora Heisterkamp, PhD, Yong-Mi Kim, MD

Blood (2008) 112 (11): 2922.

https://doi.org/10.1182/blood.V112.11.2922.2922

Published: 2008

Journal Articles

Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia.

Yong-Mi Kim, MD, MPH, Eugene Park, Colin Lorentzen, Brian De La Torre, Yao-Te Hsieh, Hannah Whang, Lars Klemm, Cu Nguyen, PhD, Michael McMillan, PhD, Jia-Ling Teo, PhD, Markus Muschen, MD, Michael Kahn, PhD

Blood (2007) 110 (11): 1596.

https://doi.org/10.1182/blood.V110.11.1596.1596

Published: 2007

NARROW

Integrin α6 mediates the drug resistance of acute lymphoblastic B-cell leukemia

Integrin alpha6-Deletion Induces Apoptosis and Src Signaling Changes in Acute Lymphoblastic Leukemia Cells

Enhanced Targeting of FLT3-ITD+AML Stem Cells through Combined Inhibition of SIRT1 and Autophagic Flux

Overcoming Drug Resistance of Pre-B ALL Cells By Targeting Integrin alpha6 Associated Cell-Adhesion Mediated Drug Resistance Using a Novel Antibody, P5G10

Increased p53 Acetylation By SIRT1 Inhibition Is Required for Optimal Activation of p53 Activity and Significantly Enhances the Ability of HDM2 Inhibitors to Target CML LSC

PI3Kdelta Inhibitor, CAL-101, De-Adheres Primary Pre-B ALL from VCAM-1 and Induces Apoptosis in Primary Pre-B ALL

VLA4 Blockade In Acute Myeloid Leukemia

Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy

The Small Molecule Inhibitor of VLA4 TBC3486 Sensitizes Resistant ALL to Chemotherapy

Functional Modulation of VLA6 in BCR-ABL1+ Pre-B Acute Lymphoblastic Leukemia.

Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia

Adjuvant CD49d Blockade Eradicates Chemoresistant ALL

Targeting Survivin In Recalcitrant Acute Lymphoblastic Leukemia

Overcoming Drug Resistance In Acute Lymphoblastic Leukemia by Inhibition of CBP/γ-Catenin

Targeting Survivin Using ICG-001 May Overcome Drug Resistance in Primary B-Cell Acute Lymphoblastic Leukemia.

Role of Survivin in Drug Resistant B-Cell Acute Lymphoblastic Leukemia.

Preclinical Evaluation of Tysabri as a Novel Adjuvant Therapy against Drug Resistant B-ALL.

Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL

Preclinical Evaluation of CBP/β-catenin Inhibition as a New Strategy for Drug Resistant Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only